193 related articles for article (PubMed ID: 37667113)
1. SAMHD1 expression is a surrogate marker of immune infiltration and determines prognosis after neoadjuvant chemotherapy in early breast cancer.
Gutiérrez-Chamorro L; Felip E; Castellà E; Quiroga V; Ezeonwumelu IJ; Angelats L; Esteve A; Perez-Roca L; Martínez-Cardús A; Fernandez PL; Ferrando-Díez A; Pous A; Bergamino M; Cirauqui B; Romeo M; Teruel I; Mesia R; Clotet B; Riveira-Muñoz E; Margelí M; Ballana E
Cell Oncol (Dordr); 2024 Feb; 47(1):189-208. PubMed ID: 37667113
[TBL] [Abstract][Full Text] [Related]
2. SPAG5 as a prognostic biomarker and chemotherapy sensitivity predictor in breast cancer: a retrospective, integrated genomic, transcriptomic, and protein analysis.
Abdel-Fatah TMA; Agarwal D; Liu DX; Russell R; Rueda OM; Liu K; Xu B; Moseley PM; Green AR; Pockley AG; Rees RC; Caldas C; Ellis IO; Ball GR; Chan SYT
Lancet Oncol; 2016 Jul; 17(7):1004-1018. PubMed ID: 27312051
[TBL] [Abstract][Full Text] [Related]
3. Immune microenvironment changes induced by neoadjuvant chemotherapy in triple-negative breast cancers: the MIMOSA-1 study.
Sarradin V; Lusque A; Filleron T; Dalenc F; Franchet C
Breast Cancer Res; 2021 May; 23(1):61. PubMed ID: 34039396
[TBL] [Abstract][Full Text] [Related]
4. DNA methylation changes in response to neoadjuvant chemotherapy are associated with breast cancer survival.
Pedersen CA; Cao MD; Fleischer T; Rye MB; Knappskog S; Eikesdal HP; Lønning PE; Tost J; Kristensen VN; Tessem MB; Giskeødegård GF; Bathen TF
Breast Cancer Res; 2022 Jun; 24(1):43. PubMed ID: 35751095
[TBL] [Abstract][Full Text] [Related]
5. SAMHD1 expression modulates innate immune activation and correlates with ovarian cancer prognosis.
Gutiérrez-Chamorro L; Felip E; Bernat-Peguera A; Ezeonwumelu IJ; Teruel I; Martínez-Cardús A; Clotet B; Riveira-Muñoz E; Romeo M; Margelí M; Ballana E
Front Immunol; 2023; 14():1112761. PubMed ID: 36845138
[TBL] [Abstract][Full Text] [Related]
6. Expression of Cyclin D1 protein in residual tumor after neoadjuvant chemotherapy for breast cancer.
Villegas SL; Darb-Esfahani S; von Minckwitz G; Huober J; Weber K; Marmé F; Furlanetto J; Schem C; Pfitzner BM; Lederer B; Engels K; Kümmel S; Müller V; Mehta K; Denkert C; Loibl S
Breast Cancer Res Treat; 2018 Feb; 168(1):179-187. PubMed ID: 29177689
[TBL] [Abstract][Full Text] [Related]
7. FOXA1 expression after neoadjuvant chemotherapy is a prognostic marker in estrogen receptor-positive breast cancer.
Kawase M; Toyama T; Takahashi S; Sato S; Yoshimoto N; Endo Y; Asano T; Kobayashi S; Fujii Y; Yamashita H
Breast Cancer; 2015 May; 22(3):308-16. PubMed ID: 23771556
[TBL] [Abstract][Full Text] [Related]
8. Strong CD8+ lymphocyte infiltration in combination with expression of HLA class I is associated with better tumor control in breast cancer patients treated with neoadjuvant chemotherapy.
de Groot AF; Blok EJ; Charehbili A; Engels CC; Smit VTHBM; Dekker-Ensink NG; Putter H; Meershoek-Klein Kranenbarg E; van de Velde CJH; Liefers GJ; Nortier JWR; Kuppen PJK; van der Burg SH; Kroep JR
Breast Cancer Res Treat; 2019 Jun; 175(3):605-615. PubMed ID: 30868392
[TBL] [Abstract][Full Text] [Related]
9. Clinical and biological impact of miR-18a expression in breast cancer after neoadjuvant chemotherapy.
Luengo-Gil G; García-Martínez E; Chaves-Benito A; Conesa-Zamora P; Navarro-Manzano E; González-Billalabeitia E; García-Garre E; Martínez-Carrasco A; Vicente V; Ayala de la Peña F
Cell Oncol (Dordr); 2019 Oct; 42(5):627-644. PubMed ID: 31115881
[TBL] [Abstract][Full Text] [Related]
10. TRAF6 and TAK1 Contribute to SAMHD1-Mediated Negative Regulation of NF-κB Signaling.
Espada CE; St Gelais C; Bonifati S; Maksimova VV; Cahill MP; Kim SH; Wu L
J Virol; 2021 Jan; 95(3):. PubMed ID: 33177202
[TBL] [Abstract][Full Text] [Related]
11. Prognostic significance of pathologic complete response and Ki67 expression after neoadjuvant chemotherapy in breast cancer.
Yoshioka T; Hosoda M; Yamamoto M; Taguchi K; Hatanaka KC; Takakuwa E; Hatanaka Y; Matsuno Y; Yamashita H
Breast Cancer; 2015 Mar; 22(2):185-91. PubMed ID: 23645542
[TBL] [Abstract][Full Text] [Related]
12. Analysis of the relevance between molecular subtypes and efficacy of neoadjuvant chemotherapy in breast cancer as well as its prognostic factors.
Li F; Ma L; Geng C; Liu C; Deng H; Yue M; Ding Y; Wang X; Liu Y
Pathol Res Pract; 2018 Aug; 214(8):1166-1172. PubMed ID: 29945816
[TBL] [Abstract][Full Text] [Related]
13. Tumor-infiltrating immune cell profiles and their change after neoadjuvant chemotherapy predict response and prognosis of breast cancer.
García-Martínez E; Gil GL; Benito AC; González-Billalabeitia E; Conesa MA; García García T; García-Garre E; Vicente V; Ayala de la Peña F
Breast Cancer Res; 2014 Nov; 16(6):488. PubMed ID: 25432519
[TBL] [Abstract][Full Text] [Related]
14. Overview of resistance to systemic therapy in patients with breast cancer.
Gonzalez-Angulo AM; Morales-Vasquez F; Hortobagyi GN
Adv Exp Med Biol; 2007; 608():1-22. PubMed ID: 17993229
[TBL] [Abstract][Full Text] [Related]
15. An immunological signature to predict outcome in patients with triple-negative breast cancer with residual disease after neoadjuvant chemotherapy.
Blaye C; Darbo É; Debled M; Brouste V; Vélasco V; Pinard C; Larmonier N; Pellegrin I; Tarricone A; Arnedos M; Commeny J; Bonnefoi H; Larmonier C; MacGrogan G
ESMO Open; 2022 Aug; 7(4):100502. PubMed ID: 35759853
[TBL] [Abstract][Full Text] [Related]
16. Tumor Immune Microenvironment and Response to Neoadjuvant Chemotherapy in Hormone Receptor/HER2+ Early Stage Breast Cancer.
Vanguri RS; Fenn KM; Kearney MR; Wang Q; Guo H; Marks DK; Chin C; Alcus CF; Thompson JB; Leu CS; Hibshoosh H; Kalinsky KM; Mathews JC; Nadeem S; Hollmann TJ; Connolly EP
Clin Breast Cancer; 2022 Aug; 22(6):538-546. PubMed ID: 35610143
[TBL] [Abstract][Full Text] [Related]
17. Impact of biomarker changes during neoadjuvant chemotherapy for clinical response in patients with residual breast cancers.
Enomoto Y; Morimoto T; Nishimukai A; Higuchi T; Yanai A; Miyagawa Y; Murase K; Imamura M; Takatsuka Y; Nomura T; Takeda M; Watanabe T; Hirota S; Miyoshi Y
Int J Clin Oncol; 2016 Apr; 21(2):254-261. PubMed ID: 26338270
[TBL] [Abstract][Full Text] [Related]
18. COGNITION: a prospective precision oncology trial for patients with early breast cancer at high risk following neoadjuvant chemotherapy.
Pixberg C; Zapatka M; Hlevnjak M; Benedetto S; Suppelna JP; Heil J; Smetanay K; Michel L; Fremd C; Körber V; Rübsam M; Buschhorn L; Heublein S; Schäfgen B; Golatta M; Gomez C; von Au A; Wallwiener M; Wolf S; Dikow N; Schaaf C; Gutjahr E; Allgäuer M; Stenzinger A; Pfütze K; Kirsten R; Hübschmann D; Sinn HP; Jäger D; Trumpp A; Schlenk R; Höfer T; Thewes V; Schneeweiss A; Lichter P
ESMO Open; 2022 Dec; 7(6):100637. PubMed ID: 36423362
[TBL] [Abstract][Full Text] [Related]
19. The potential prognostic value of connexin 26 and 46 expression in neoadjuvant-treated breast cancer.
Teleki I; Krenacs T; Szasz MA; Kulka J; Wichmann B; Leo C; Papassotiropoulos B; Riemenschnitter C; Moch H; Varga Z
BMC Cancer; 2013 Feb; 13():50. PubMed ID: 23374644
[TBL] [Abstract][Full Text] [Related]
20. Molecular types and neoadjuvant chemotherapy in patients with breast cancer- while molecular shifting is more common in luminal a tumors, the pathologic complete response is most frequently observed in her-2 like tumors.
Salim DK; Mutlu H; Eryilmaz MK; Musri FY; Tural D; Gunduz S; Coskun HS
Asian Pac J Cancer Prev; 2014; 15(21):9379-83. PubMed ID: 25422228
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
